Off-tumor target--beneficial site for antiangiogenic cancer therapy?
Antiangiogenic cancer therapy is based on agents that target blood vessels of the tumor to inhibit its growth. However, experience from the clinic demonstrates that survival benefits following antiangiogenic therapy do not always correlate with tumor size and growth inhibition. Emerging evidence shows that delivery of antiangiogenic drugs might induce systemic alterations of the vasculature that modulate the function of various tissues and organs. Normalization of tissues and organs by antiangiogenic therapy may be an important mechanism underlying the survival benefits seen in patients with cancer who suffer cancer-associated systemic syndromes. This new concept has been validated in preclinical tumor models, and responses in patients have positively correlated with clinical benefits.
Cao
Yihai
Y
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Nobelsväg 16, Solna Campus, Box 280, 171 77 Stockholm, Sweden. yihai.cao@ki.se
D043925:Angiogenesis Inducing Agents / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A